Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes.

Pandya N, DiGenio A, Gao L, Patel M.

Drugs Aging. 2013 Jun;30(6):429-38. doi: 10.1007/s40266-013-0069-9.

PMID:
23539233
[PubMed - indexed for MEDLINE]
2.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
[PubMed - indexed for MEDLINE]
3.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
4.

Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.

McKeage K, Goa KL.

Drugs. 2001;61(11):1599-624. Review.

PMID:
11577797
[PubMed - indexed for MEDLINE]
5.

Insulin detemir: a review of its use in the management of diabetes mellitus.

Keating GM.

Drugs. 2012 Dec 3;72(17):2255-87. doi: 10.2165/11470200-000000000-00000. Review.

PMID:
23110609
[PubMed - indexed for MEDLINE]
6.

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

Ilag LL, Kerr L, Malone JK, Tan MH.

Clin Ther. 2007 Jun;29(6 Pt 1):1254-70. Review.

PMID:
18036388
[PubMed - indexed for MEDLINE]
7.

Biphasic insulin aspart 30: literature review of adverse events associated with treatment.

Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.

Clin Ther. 2005;27 Suppl B:S75-88. Review.

PMID:
16519039
[PubMed - indexed for MEDLINE]
8.

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. Review.

PMID:
17443605
[PubMed - indexed for MEDLINE]
9.

Dosing of insulin glargine in the treatment of type 2 diabetes.

Barnett A.

Clin Ther. 2007 Jun;29(6):987-99. Review.

PMID:
17692716
[PubMed - indexed for MEDLINE]
10.

Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.

Duckworth W, Davis SN.

J Diabetes Complications. 2007 May-Jun;21(3):196-204. Review.

PMID:
17493554
[PubMed - indexed for MEDLINE]
11.

Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.

McKeage K, Goa KL.

Treat Endocrinol. 2002;1(1):55-8. Review.

PMID:
15765621
[PubMed - indexed for MEDLINE]
12.

Efficacy of biphasic insulin aspart in patients with type 2 diabetes.

Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.

Clin Ther. 2005;27 Suppl B:S57-74. Review.

PMID:
16519038
[PubMed - indexed for MEDLINE]
13.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
14.

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

Ilag LL, Kerr L, Malone JK, Tan MH.

Clin Ther. 2007;29 Spec No:1254-70. Review.

PMID:
18046926
[PubMed - indexed for MEDLINE]
15.

Glargine safety, diabetes and cancer.

Rendell M, Akturk HK, Tella SH.

Expert Opin Drug Saf. 2013 Mar;12(2):247-63. doi: 10.1517/14740338.2013.770469. Epub 2013 Feb 11. Review.

PMID:
23394441
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk